Vera Therapeutics, Inc.’s VERA share price has surged by 6.17%, which has investors questioning if this is right time to sell.

BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of ...

Vera Therapeutics (VERA) announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA ...

In a report released today, Vamil Divan from Guggenheim reiterated a Buy rating on Vera Therapeutics (VERA – Research Report), with a price ...

Get the next trade alert free. Vera Therapeutics, Inc. VERA said on Wednesday that it had completed full enrollment (431 participants) in the pivotal ORIGIN Phase 3 trial of atacicept in patients ...

Highlights,Wellington Management Group LLP reduced its holdings in Vera Therapeutics during the fourth quarter.,Schroder Investment Management and Pictet Asset Management increased their equity ...

BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative ...

Investing.com’s Fair Value model demonstrated remarkable accuracy in identifying overvalued stocks, as evidenced by its September 2024 analysis of Vera Therapeutics (NASDAQ:VERA). The model’s ...

BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting ...